Articles

Promoting research, innovation and competition: the reform of the clin…

22/05/2013

Promoting research, innovation and competition: the reform of the clinical trials legislation in the EUCatherine McLoughlin

With changes proposed to the clinical trials regime in the EU, we look at the principal changes being considered and assess their potential impact on the conduct of research and...

Read more

How doctors prefer to engage with pharma: part three

21/05/2013

How doctors prefer to engage with pharma: part threeDoctor C

 In part of three of this series, Hannah Blake interviews an oncologist (who will be referred to as Doctor C) about his thoughts on the interaction between physicians and pharma. (Continued...

Read more

Digital health perspectives: Francesco Raimo

21/05/2013

Digital health perspectives: Francesco RaimoFrancesco Raimo

pharmaphorum's Rebecca Aris caught up with the Digital Director of Life Healthcare Communications, Francesco Raimo, to hear his views on digital in healthcare. Francesco Raimo comes from a technical background, as...

Read more

Welcome to the new online home of the pharma industry

20/05/2013

Welcome to the new online home of the pharma industryPaul Tunnah

You might have noticed that things have changed on pharmaphorum recently, with the launch of our new website, so Paul Tunnah muses this month on some of the key changes...

Read more

News

Phase 2 trials show Sanofi, Regeneron drug reduces risk of asthma atta…

21/05/2013

Phase 2 trials show Sanofi, Regeneron drug reduces risk of asthma attacks by 87%Hannah Blake

Postive phase 2 clinical trial data of Sanofi and Regeneron's asthma treatment, dupilumab, have today been published in the New England Journal of Medicine. The study found that dupilumab (Sis...

Read more

Bayer reports positive phase 3 data for lung drug

21/05/2013

Bayer reports positive phase 3 data for lung drugHannah Blake

Bayer has announced positive data from the interim analysis of its experimental riociguat drug to treat patients with pulmonary arterial hypertension (PAH). In the extension of a phase 3 clinical trial,...

Read more

Actavis to acquire Warner Chilcott for $8.5bn

20/05/2013

Actavis to acquire Warner Chilcott for $8.5bnHannah Blake

Generic drugmaker Actavis has entered into a definitive agreement to acquire the international pharma company Warner Chilcott plc for US $8.5 billion. If successfully completed, this transaction will create the third-largest...

Read more

India’s new drug pricing policy comes into effect

20/05/2013

India’s new drug pricing policy comes into effectHannah Blake

The Government of India's Department of Pharmaceuticals announced last week that the Drug Price Control Order 2013 will come into effect immediately. This new order authorizes the National Pharmaceutical Pricing Authority...

Read more

Audio & Video

White Papers

Doctors hold the key to understanding pa…

Doctors hold the key to understanding patient outcomesCarly Brown

Pharma is recognising the increasing importance of the patient voice in providing feedback on how medicines are utilised in a real-world setting and the impact they are having on outcomes....

View info

Outcomes shape the new payer networks fo…

Outcomes shape the new payer networks for pharmaMarcelo Fantoni

The definition of the payer and the way in which healthcare spending decisions are made is changing, as complex networks of payers and clinicians become the new stakeholders with which...

View info

Publishing white papers on pharmaphorum

Publishing white papers on pharmaphorumPaul Tunnah

As a new feature on pharmaphorum, we unveil pharmaceutical industry white papers as part of our media section. Download this one page document to understand how to publish your deep...

View info

Further News & Articles

Finding the right way to listen to patients

As our market access month continues and pharma seeks closer patient engagement to better understand real-world o...

Read more

Articles

Janssen’s ulcerative colitis drug approved by US FDA

Janssen Biotech, one of Johnson & Johnson's pharma companies, has announced the FDA approval of its ulcerative co...

Read more

News

The reimbursement environment in Europe

In our market access themed month, Sophia Tickell comments on the reimbursement landscape in healthcare across Eu...

Read more

Articles

Sanofi reports positive phase 3 myelofibrosis study results

Sanofi has announced that its rare disease treatment to treat myelofibrosis showed positive results in a late-stage p...

Read more

News

The enemy within

Sam Olsen warns that the greatest threat to Pharmaceutical and Biotech corporate Intellectual Property (...

Read more

Articles

Bayer’s prostate cancer drug wins early FDA approval

Bayer's new prostate cancer drug has been approved in the US three months ahead of schedule through the FDA's priorit...

Read more

News